Skip to main content
Equibles
TELA logo

TELA · TELA Bio, Inc.

Track TELA — free

Use TELA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TELA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.15 -0.09 (-7.26%) At close · Sep 30
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. Accordingly, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”
View the 10-Q filed Aug 11, 2026
Market Cap
$56.57M
Shares
44.89M
Volume · Sep 30 94K Avg daily vol (3M) 202.38K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.15 Open$1.25 Day$1.15–1.25 52W close$0.56–1.57 Avg vol 30d294K Short int551K · 1.2% float · 2.2d Short vol38% Last earningsAug 10, 2026 DataJan 2020–Sep 2026 Filing10-Q · Aug 11

Up next

Next earnings call
Nov 10, 2026 Est · unconfirmed · in 6 wks
Latest filing: 10-Q
filed Aug 11, 2026
Q1 2026 earnings call transcript
call held May 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$79.91M
Trailing 12 months
Net income (TTM)
−$41.18M
Trailing 12 months
Revenue growth YoY
-4.5%
Year over year
Operating margin
-42.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-55.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+26.6%
Year over year · more shares
Price change (1Y)
-17.3%
Trailing year
Short interest
1.2%
Latest settlement · 2.2 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Strong Sentiment Bullish Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 16.3 · calm Equity put/call 0.53
Technical
price trend
Buy
50 / 200-day cross Golden cross
Price vs 200-day avg +33%
above
Price vs 50-day avg +31%
above
RSI (14) 57
neutral
MACD trend Negative
52-week position 58%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return +45%
trailing
6-month return +93%
trailing
YTD return −3%
this year
Relative strength +81%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Accumulating
+25% holders QoQ · +10 funds added
Insider flow Accumulating
Net +$186.0K over 90 days · 0% sells
Short interest Rising
1.23% of float · ▲ +43.2% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
45 holders — mid 3-yr range
Squeeze score 67
elevated · 0–100
Fundamentals
Excellent
Revenue growth +16%
Y/Y
Gross margin 68%
expanding
EPS growth +38%
Y/Y
Free cash flow $-28.7M
Balance sheet $11.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 92%
annualized · 1-yr
Max drawdown −64%
past year
ATR 9.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 3 of last 4
Latest guidance · from the 8-K filed Mar 24, 2026
Full year 2026 revenue growth of at least 8% over full year 2025 · Full year 2026 Initiated at least 8%
Prior guidance period ended · from the 8-K filed Mar 24, 2026
First quarter 2026 revenue of approximately $18.5 million · First quarter 2026 $18.5M
Guided vs delivered · last 4 settled
First quarter 2026 revenue of approximately $18.5 million First quarter 2026
guided $18.5M
$19.06M Beat +3.0%
Full year 2024 revenue full year 2024
guided $74.5M – $76.5M
$69.3M Miss −8.2%
Full year 2023 revenue full year 2023
guided $57M – $60M
$58.45M In line
Revenues full year 2021
guided $28M – $30M
$29.46M In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 3 · 3
50 / 200-day cross
Golden cross Bullish
Price vs 200-day avg
+33% Bullish
Price vs 50-day avg
+31% Bullish
RSI (14)
57 Neutral
MACD trend
Negative Bearish
52-week position
58% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) Golden cross
50d $1 › 200d $1 — 50d above 200d
Institutional flow Accumulating
+25% holders QoQ · +10 funds added
Insider flow Accumulating
Net +$186.0K over 90 days · 0% sells
Short interest Rising
1.23% of float · ▲ +43.2% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
45 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 58% Range high $2
vs 200-day avg +33% vs 50-day avg +31% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
OviTex PRS units sold 1,050 the three months ended June 30, 2026 filing —
OviTex units sold 5,776 the three months ended June 30, 2026 filing —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Medical Devices — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TELA
TELA Bio, Inc.
this stock
$56.57M -2.5% +15.8% — 1.2%
ABT
Abbott Laboratories
 $174.90B -21.1% +5.7% 28.1 1.1%
MDT
Medtronic plc
 $113.38B -10.2% +8.4% 21.8 1.3%
SYK
Stryker Corp
 $104.47B -21.6% +11.2% 28.2 2.0%
BSX
Boston Scientific Corp
 $63.59B -54.2% +12.5% 17.8 3.2%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
45
% held
57.4%
Net QoQ
-1.9M sh
Top holder
Essex Woodlands Managemen…
Held Float
View
Held by Funds
Fund positions
11
View
Short & Settlement
Short Interest Rising
Shares short
550.8K
Days to cover
2.2d
Change
+166.2K sh
View
Short Volume
Short vol %
38%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
864
Value
$648
As of
Sep 3, 2026
View
Off-Exchange
Off-exchange %
91.0%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$186.0K
Buyers / Sellers
2 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$80.3M
Net income (FY)
$-38.8M
EPS diluted
$-0.83
View
Filings
SEC Filings
Latest
8-K
Filed
Sep 29, 2026
This year
16
View
Proposed Sales
Value
$2.2M
Shares
428.4K
Filed
Jun 28, 2024
View
Earnings & Events
Earnings Calls
Last call
Aug 10, 2026
View

Performance

5D 20D 120D MTD YTD
TELA -11.5% +45.3% +93.0% +55.8% -2.5%
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY -10.9% +45.2% +80.8% +56.4% -14.4%
Key facts CIK 1561921 CUSIP 872381108 13F (30d) 1 filings 1 filers Visit website Investor relations